Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹12,965 Cr revenue.
COGS 36.7%, employees 18.9%.
“we gave an overall guidance of a double digit kind of growth assuming the market grows at around 8% to 8.”
“I see somewhere between 19.”
“we'll continue to outperform the market at least by 100 to 150 basis points.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.8%▲ | 10.5% |
| ROCE | 19.3%▲ | 13.8% |
| Net Margin | 16.0%▲ | 8.7% |
| EBITDA Margin | 22.8%▲ | 16.0% |
| Debt To Equity | 0.15x▼ | 0.21x |
| Rev Growth 3yr | 7.6%▲ | 5.8% |
| EPS Growth 3yr | 9.6%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14,253 Cr +9.9% | ₹12,965 Cr +2.3% | ₹12,668 Cr +9.2% | ₹11,599 Cr +9.1% | ₹10,634 Cr +20.0% | ₹8,865 Cr +6.2% | ₹8,344 Cr +13.4% | ₹7,357 Cr |
| Other Income | ₹529 Cr +7.2% | ₹494 Cr +58.8% | ₹311 Cr +43.9% | ₹216 Cr +32.8% | ₹163 Cr -30.3% | ₹233 Cr +123.8% | ₹104 Cr +18.8% | ₹88 Cr |
| Total Income | ₹14,782 Cr +9.8% | ₹13,458 Cr +3.7% | ₹12,978 Cr +9.8% | ₹11,815 Cr +9.4% | ₹10,797 Cr +18.7% | ₹9,098 Cr +7.7% | ₹8,449 Cr +13.5% | ₹7,445 Cr |
| COGS | ₹5,124 Cr +7.6% | ₹4,764 Cr -3.5% | ₹4,938 Cr +0.6% | ₹4,907 Cr +17.4% | ₹4,180 Cr +19.5% | ₹3,498 Cr +4.6% | ₹3,345 Cr +13.6% | ₹2,945 Cr |
| ₹11,898 Cr +8.8% | ₹10,931 Cr +0.9% | ₹10,834 Cr +4.1% | ₹10,408 Cr +16.4% | ₹8,938 Cr +23.2% | ₹7,256 Cr +0.9% | ₹7,189 Cr +10.8% | ₹6,490 Cr | |
| Profit Before Tax | ₹2,844 Cr +12.6% | ₹2,527 Cr +24.9% | ₹2,023 Cr +55.1% | ₹1,305 Cr -29.3% | ₹1,844 Cr +0.1% | ₹1,842 Cr +46.2% | ₹1,260 Cr +32.0% | ₹955 Cr |
| Exceptional Items | (₹40 Cr) | ₹0.00 Cr +100.0% | (₹121 Cr) -18.0% | (₹103 Cr) -588.2% | (₹15 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹420 Cr +35.0% | ₹311 Cr +46.9% | ₹212 Cr -29.0% | ₹298 Cr +81.7% | ₹164 Cr -26.9% | ₹224 Cr +103.1% | ₹110 Cr -39.0% | ₹181 Cr | |
| Net Profit | ₹2,422 Cr +9.3% | ₹2,215 Cr +22.3% | ₹1,811 Cr +79.9% | ₹1,007 Cr -40.1% | ₹1,680 Cr +3.9% | ₹1,618 Cr +40.8% | ₹1,149 Cr +48.6% | ₹774 Cr |
| Profit (Owners) | ₹2,371 Cr +9.5% | ₹2,165 Cr +20.6% | ₹1,796 Cr +82.5% | ₹984 Cr -40.2% | ₹1,646 Cr +3.8% | ₹1,585 Cr +40.6% | ₹1,127 Cr +48.2% | ₹761 Cr |
| Minority Interest | ₹51 Cr +2.7% | ₹50 Cr +218.0% | ₹16 Cr -30.7% | ₹23 Cr -34.8% | ₹35 Cr +6.0% | ₹33 Cr +47.3% | ₹22 Cr +69.4% | ₹13 Cr |
| Other Comprehensive Income | ₹66 Cr +234.3% | ₹20 Cr -1.6% | ₹20 Cr -82.6% | ₹115 Cr +236.6% | ₹34 Cr ↑ Recovery | (₹34 Cr) ↓ Decline | ₹27 Cr -13.4% | ₹31 Cr |
| EPS | ₹198.32 | ₹181.11 | ₹150.19 | ₹82.31 | ₹137.63 | ₹132.57 | ₹94.26 | ₹63.61 |
| Diluted Shares | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
| Profit Or Loss Of Associates | (₹2 Cr) -225.8% | (₹0.62 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Alkem Laboratories Limited has informed the Exchange about Schedule of meet
Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-fi...
Alkem Laboratories Limited has informed the Exchange about Transcript
Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Alkem Laboratories Limited has informed the Exchange about Investor Presentation
Alkem Laboratories Limited has informed the Exchange regarding Intimation for Cutoff date for the purpose of the Annual General Meeting.
Alkem Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 07-Aug-2026.
Alkem Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 28, 2026, recommended Final Dividend of Rs. 10 per equity share.
Alkem Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.
Alkem Laboratories Limited has submitted to the Exchange, Outcome of the Board Meeting held on 28th May, 2026
Alkem Laboratories Limited has informed the Exchange about Schedule of meet
Alkem Laboratories Limited has informed the Exchange about Conference Call on Q4FY26 and FY26.
Alkem Laboratories Limited has informed the Exchange about appointment of Senior Management Personnel
Alkem Laboratories Limited has informed the Exchange about US FDA Inspection at Company s manufacturing facility located at Amaliya, Daman